Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis
Completed · Phase 2 · NCT05570006
Conditions: Ulcerative Colitis
At a glance
- Research payments reported, 2025
- $67,891
- U.S. investigators named
- 8
- Sites paid
- 8
- Planned or actual enrollment
- 30
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-668 (drug)
- Dates
- Started 2023-03-16; completion 2024-12-23
- Results posted
- Yes
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how safe and effective ABBV-668 is in treating adult participants with UC. Adverse events and change in disease activity will be assessed. ABBV-668 is an investigational drug being developed for the treatment of moderate to severe UC. Approximately 40 adult participants diagnosed with UC will be enrolled in approximately 30 sites globally. Participants will receive oral capsules of ABBV-668 twice daily for 16 weeks and will undergo a 30 day follow-up period. There may be higher treatment burden for participa…
From ClinicalTrials.gov, last updated 2025-12-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $67,891 in research payments for this study in 2025 (14 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Erick H. Alayo, M.D. Gastroenterology · Chula Vista, CA
- Peter H. Gach, MD Gastroenterology · Margate, FL
- Andria M. Mushahwar, MD Gastroenterology · Maitland, FL
- Lev Ginzburg, M.D. Gastroenterology · New Hyde Park, NY
- Arun Swaminath, M.D. Gastroenterology · New York, NY
- Harvey A. Tatum, MD Gastroenterology · Tulsa, OK
- Faten N. Aberra, MD Gastroenterology · Philadelphia, PA
- Sandra M. El-hachem, MD Gastroenterology · Pittsburgh, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Hospital of Univ of Pennsylvania, PA $23,468
- New York University $18,276
- $11,200
- Feinstein Institute for $5,835
- Erick H Alayo Medical Corporation $3,000
- Atlantic Medical Research LLC $1,799
- Cfagi LLC $1,613
- Options Health Research LLC $1,500
- Allegheny Singer Research Institute $1,200
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.